The dataset that was used is held by the National Health Insurance Fund (NHIF) of Hungary (<http://www.neak.gov.hu>, e-mail: <neak@neak.gov.hu>). Access to the individual-level data is available after filing a formal data access request to <adatkeres@neak.gov.hu>. Requestors need to accept the terms and conditions of the data request and may need to pay the corresponding data access fee. The terms of the contract for data access does not allow the reporting of any data of a single individual or results which comes from aggregating the data of less than 10 individuals. Therefore, a de-identified dataset could not be provided. Taking these requirements into consideration, the results can be published. A supplementary dataset was created which contains the patient counts derived from the original data.

Introduction {#sec005}
============

Ulcerative colitis (UC) is a chronic inflammation of the colon with an unknown etiology. Inflammatory bowel disease (IBD) is associated with morbidity, mortality, and substantial costs to healthcare systems, therefore several studies have attempted to define the burden of the disease. The occurrence of ulcerative colitis is changing in the 21st century. The incidence and prevalence rates vary geographically. Previous studies report the highest incidence rates from industrialized countries, such as North America and Western Europe \[[@pone.0233238.ref001], [@pone.0233238.ref002]\]. The population-based study of the ECCO EpiCom-group (European Crohn's and Colitis Organization--Epidemiological Committee) revealed an east-west gradient in the incidence of IBD. They found higher incidence rates in Western European countries, and lower ones in Eastern European countries (except for Hungary), where the incidence rates were similar to the Nordic countries. \[[@pone.0233238.ref003], [@pone.0233238.ref004]\]. Almost all countries had higher incidence rates in 2010 in contrast to the older studies. These findings were validated by the 2011 ECCO-EpiCom inception cohort study with similar results. \[[@pone.0233238.ref003], [@pone.0233238.ref004]\]. The incidence of UC has increased over the second part of the 20th century in many areas with formerly low incidence rates, but it has stabilized in high-incidence areas \[[@pone.0233238.ref001], [@pone.0233238.ref005], [@pone.0233238.ref006]\]. According to previously published Hungarian studies, the incidence of UC increased from 1977 to 2001, and then stabilized, while the prevalence rate increased from 2001 to 2006 \[[@pone.0233238.ref007], [@pone.0233238.ref008]\]. The last prevalence data (0.34% for UC) originates from a study between 2011 and 2013 based on the National Health Insurance Fund (NHIF) database \[[@pone.0233238.ref009]\].

There is a gap in knowledge about whether patients suffering from UC have a higher mortality risk compared to the general population. A meta-analysis found the overall mortality similar to the general population \[[@pone.0233238.ref010]\].

The aim of our study was to describe the incidence, prevalence rate, and the mortality of the Hungarian UC population from 2010 to 2016, and to analyze the prevalence of malignancies with a special focus on colorectal cancer (CRC). The mortality data of the UC population was compared to that of the general population to determine mortality risk.

Materials and methods {#sec006}
=====================

Data collection {#sec007}
---------------

This is an observational, non-interventional, retrospective, descriptive, epidemiological study based on the National Health Insurance Fund (NHIF) social security database. This database contains financial claims data on all healthcare events of the whole population of Hungary, a population of approximately 10 million people. These include inpatient hospital stays, outpatient visits, pharmacy drug reimbursements and special drug reimbursements. Unlike similar databases from other countries, medication prescriptions carry diagnosis information as well. It also includes demographic data on the population (date of birth, gender, geographical region and date of death, where applicable). On the other hand, non-finance-related information--such as laboratory test results--are not available. The data was analyzed between 2010 and 2016.

Differentiation between Crohn's disease (CD) and UC using a financial claims database is a complex task, because a considerable number of patients can exist in the database who have both diagnosis codes at the same time. This can happen because of the difficult differentiation during the early stages of disease.

As a first step, a background population consisting of patients with either CD or UC was created. Those patients were selected who had at least two events among all relevant health care services, or at least one inpatient event with the diagnosis of UC (based on the 10th revision of the International Statistical Classification of Diseases and Related Health Problems (ICD-10) code: K51\*) or CD (ICD-10 code: K50\*) during the study period between 2010 and 2016. Back-data was available for patients from the start of 2007. The next step was to determine which of those patients with both diagnoses could be ascertained as UC patients. These patients along with those who had only UC diagnoses formed the study population. The algorithm was as follows: a patient had to have at least 80% majority of UC diagnosis codes to be classified as an UC patient.

The patient group still contained patients for whom an UC diagnosis could not be ascertained, so a further refining step, similar to the one outlined in the paper by Kurti et al, was necessary \[[@pone.0233238.ref009]\]. In this step patients were excluded if they had none of the following: any record of biological therapy (BT), any record of UC-related surgical interventions (based on Diagnosis-related group (DRG)), or record of sufficient number of drug prescriptions (defined as at least 2 dispensings of 5-aminosalicylates (5-ASA) or corticosteroids (CS) or immunosuppressants (IS) per year). This requirement on the number of prescriptions causes that patients with a short follow-up time--i.e. those who are incident in the second half of 2016 --to be easily excluded from the analysis. Therefore, the year of 2016 was excluded from the epidemiology analysis.

Survival analysis was performed on a subgroup of patients who were newly diagnosed (defined as having no UC diagnoses before) from the beginning of 2010. This means that all incident patients have at least a 3-year long UC diagnosis-free baseline period.

For comparison purposes, date of death data of a 3 to 1 matched reference population from the total Hungarian population was obtained. The matching was performed based on age (year of birth), gender and permanent residency. No information other than the date of death could be obtained for these people, therefore no other analyses regarding these controls were possible.

To analyze the incidence, the prevalence and the mortality data of the UC population, point prevalence was used at the first day of each year. Demographic data was also evaluated.

Malignant neoplasms were evaluated in the incident UC subpopulation. Malignancies were categorized based on 3-digit ICD10 codes, presence of a certain malignancy was defined as having at least 2 diagnoses in the in- or outpatient care setting after the UC diagnosis date. The presence of colorectal cancer (CRC) was analyzed in detail. CRC was defined using ICD-10 codes C15\*-C26\*. The first CRC code appearance was considered as the date of the diagnosis of CRC. Proportion of patients with certain malignancies, yearly incidence and prevalence of CRC was evaluated. Survival data of the study population were assessed. Overall survival from the time of the diagnosis of UC and from the time of the diagnosis of CRC were evaluated. Overall survival data from the diagnosis of UC were compared with the data from the matched general population.

Statistical analysis {#sec008}
--------------------

Prevalence, incidence and mortality was described using patient counts. Demographic data was characterized using histograms and median age. To compare the age of different patient groups t-tests were used.

Survival analysis was performed to analyze overall survival, Kaplan-Meier estimators were used to characterize the survival function.

Comparison of survival of two groups is performed in two cases, for all UC patients versus controls and for the two different age groups for the CRC subpopulation. The survival curves were compared using log-rank tests. A Cox proportional hazards model--using a single binary predictor for the two groups--was also used for comparison. The hazard ratio with 95% confidence interval between the two groups was given as a result. The proportional hazards assumption was tested using plots of Schoenfeld residuals.

Due to the claims nature of the data, missing data is undiscoverable in most cases. If a certain intervention or diagnosis was not recorded, there is no chance that it could be imputed in any way. Therefore, no handling of missing data was performed.

Analyses was carried out using the statistical software R 3.5.1 (R Core Team (2018). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL [https://www.R-project.org/](https://www.r-project.org/)).

Ethical approval {#sec009}
----------------

This study has been approved by Medical Research Council--Research and Ethics Committee (TUKEB), Hungary (Appr. no: 12288-3/2018/EKU).

All data used in the study was held by NHIF, the researchers had access only to anonymized data. Data protection guidelines did not permit the reporting of patient level data even in anonymized form, only aggregate results could be reported.

The database contains information on the full population of Hungary (approximately 10 million people), the total number of patients whose data entered the patient selection algorithm was 224 175. The study population consisted of 37 795 patients after applying all inclusion and exclusion criteria.

Results {#sec010}
=======

Epidemiology of UC, demographics {#sec011}
--------------------------------

For the reasons outlined in the Materials and methods section, the incident patients in 2016 were excluded from the epidemiology analysis.

The number of patients suffering from UC between 2010--2015 was 36 315. The annual prevalence increased during the examined period ([Fig 1](#pone.0233238.g001){ref-type="fig"}). In 2010 0.24%, while in 2015 0.34% of the total Hungarian population suffered from UC.

![The annual prevalence of ulcerative colitis in Hungary.](pone.0233238.g001){#pone.0233238.g001}

A decreasing trend was found in the incidence of UC within the study period. This could be at least partly attributed to the way the diagnosis was defined, which is a limitation of our study. In 2010 there was only a 3-year baseline period for patients, while in 2015 this baseline period was longer (8 years). This causes that patients incident in real life before 2007 with longer gaps in their medical history of UC have a chance to be identified as an incident patient at the beginning of the study but this probability is much smaller in the later years. Therefore, the least biased estimate of incidence is the one from 2015 --as 2016 had to be excluded for reasons outlined in the Materials and methods section. This estimated incidence of UC from 2015 was 21.7/100 000 inhabitants.

The proportion of females amongst the prevalent population was 55%. The median age of patients at the time of the first diagnosis of UC was 51 years (males 49, females 53). The average and median age was higher for women which is demonstrated clearly on the population pyramid ([Fig 2](#pone.0233238.g002){ref-type="fig"}). The difference is statistically significant at p\<0.001.

![The population pyramid (distribution by age and gender) of the prevalent UC population at the time of diagnosis.](pone.0233238.g002){#pone.0233238.g002}

In total 3 188 prevalent patients died in the study period between 2010 and 2015. The annual mortality rate between 2011 and 2015 was stable, varying between 18.7 and 23.3 per 1000 patients. The rate was considerably lower in 2010 (12.8/1000 patients), though ([Fig 3](#pone.0233238.g003){ref-type="fig"}).

![Mortality rate of UC patients between 2010 and 2015.](pone.0233238.g003){#pone.0233238.g003}

The median age at the time of death was 75.3 years in the whole UC population. Men died at a younger age (median 71.9) than women (median 78.3) which is in concordance with the trend observable in the general population of Hungary.

Malignancies of UC patients {#sec012}
---------------------------

There were 16 712 patients who were diagnosed for the first time during the observational period (incident population). Investigating all malignant neoplasms of this incident UC population, CRC was found to be the most common cancer followed by non-melanotic skin cancer and prostate cancer ([Fig 4](#pone.0233238.g004){ref-type="fig"}).

![The number of patients diagnosed with certain types of malignant cancers.\
MN--malignant neoplasm of, Sec. MN--secondary malignant neoplasm of, (other&unspec)--other or unspecified part/type, NHL--non-Hodgkin's lymphoma, MM--multiple myeloma.](pone.0233238.g004){#pone.0233238.g004}

As CRC was the most commonly appearing malignancy, and because it can be the effect of long-term UC, it was analyzed in detail. In total 1 424 patients (8.5%) were diagnosed with CRC in the incident patient subpopulation. The number of new diagnoses was stable within the study period with roughly 200 new cases every year ([Fig 5](#pone.0233238.g005){ref-type="fig"}). A small decrease in the numbers is observable in 2015 and 2016. These results may be biased due to the methodology where two diagnoses of CRC were required for a patient to be considered. With shorter follow-up times the probability of a second diagnosis appearing can be lower.

![Incidence of CRC in the incident UC population.\
Diagnosis of UC and CRC is not necessarily in the same year.](pone.0233238.g005){#pone.0233238.g005}

Among patients with CRC 470 (33%) have died, these deaths make up 25% of all deaths within the incident UC population.

The median age of patients at the time of CRC diagnosis was 65.8 years (male: 64.7; female: 67.0). The median age of these patients at the time of death was 71.1 years (male: 68.9; female: 73.3). These patients died at a younger age than the average patient with UC as the median age at the time of death within the incident UC population was 75.3 years (male: 71.9; female: 78.3).

Survival of UC and CRC patients {#sec013}
-------------------------------

Overall survival of the incident UC patients from the time of diagnosis was examined ([Fig 6](#pone.0233238.g006){ref-type="fig"}). The survival probability decreased with increasing time elapsed at a linear rate. The 1-year survival rate was 97%, the 3-year survival rate was 91% and the 5-year survival rate was 86%.

![Overall survival of UC patients and matched controls from diagnosis.\
Start: UC diagnosis date for UC patients, UC diagnosis date of matched patients for controls. Event: death. Censoring: end of data availability (end of 2016). Shaded areas denote 95% confidence bands.](pone.0233238.g006){#pone.0233238.g006}

UC patients have significantly worse survival than their matched controls (HR = 1.65, 95% CI: 1.56--1.75).

Overall survival of CRC patients amongst the UC patients from the CRC diagnosis was also analyzed ([Fig 7](#pone.0233238.g007){ref-type="fig"}). The survival probability decreased with increasing time elapsed at a linear rate. The 1-year survival rate was 88%, the 3-year survival rate was 75% and the 5-year survival rate was 65%. The median survival was 9.67 years.

![Overall survival of CRC patients amongst the UC patients from CRC diagnosis.\
Start: CRC diagnosis date. Event: death. Censoring: end of data availability (end of 2016). Shaded area denotes 95% confidence band.](pone.0233238.g007){#pone.0233238.g007}

This analysis was also performed using a breakdown of patients based on age (over and under 60 years) ([Fig 8](#pone.0233238.g008){ref-type="fig"}). No significant difference could be found between the survival probabilities of these two age groups (HR = 1.18, 95% CI: 0.94--1.46, p = 0.147).

![Overall survival of CRC patients amongst the UC patients from CRC diagnosis by age.\
Start: CRC diagnosis date. Event: death. Censoring: end of data availability (end of 2016). Shaded areas denote 95% confidence bands.](pone.0233238.g008){#pone.0233238.g008}

Discussion {#sec014}
==========

This is the first population-based study from Eastern Europe, which simultaneously estimates the prevalence and incidence rates, the mortality and the morbidity and the associated malignancy data based on the Hungarian National Health Insurance Fund database. In the present study, the prevalence of UC in the Hungarian population increased from 0.24% to 0.34%. Based on previous Hungarian studies, the prevalence rate of UC was 10.4/100 000 people from 1962--1992, 142.6/100 000 from 1991 to 2001 and 211.1/100 000 from 2002--2006 (that corresponds to 0.01% between 1962 and 1992, to 0.14% between 1991 and 2001, and to 0.21% between 2002 and 2006) \[[@pone.0233238.ref007], [@pone.0233238.ref008], [@pone.0233238.ref011]\]. A Hungarian population-based study between 2011 and 2013 based on the National Health Insurance Fund database found a prevalence of 0.34% for UC patients \[[@pone.0233238.ref009]\], which is similar to our findings. They found the highest prevalence in Western Hungary (0.49%), and in the South-West region (0.35%).

Based on previous Hungarian studies, the incidence rate of UC has been increasing, it was 1.4/100 000 from 1962 to 1992, 5.89/100 000 from 1997 to 2001, 11.9/100 00 from 2002 to 2006 \[[@pone.0233238.ref007], [@pone.0233238.ref008], [@pone.0233238.ref011]\]. The incidence of 21.7/100 000 inhabitants in 2015 found in our study is considerably higher than the one reported in 2006. The increasing incidence tendency is in concordance with the published data from industrialized countries. The population-based study of the ECCO EpiCom-group revealed an east-west gradient, the median crude annual incidence rates for UC were 10.8 cases per 100 000 persons in 2010 in Western European centers, while in Eastern European centers (except Hungary) it was lower (4.1/100 000). Interestingly, in Hungary the incidence rates were similar to the high incidence in Nordic countries. In the 2011 ECCO-EpiCom inception cohort the mean annual incidence rates were lower, however, on the individual center level the results corresponded to the findings in the 2010 inception cohort \[[@pone.0233238.ref003], [@pone.0233238.ref004]\]. In a population-based study of French adolescents, UC incidences increased from 1988--1990 to 2009--2011 from 1.6 to 4.1/100 000 \[[@pone.0233238.ref012]\]. The multicenter European Collaborative Study on Inflammatory Bowel Disease (EC-IBD) reported blended incidence rates between 8.7--11.8 cases per 100 000 person-years for UC \[[@pone.0233238.ref002]\]. Lower incidence and prevalence rates can be observed in other Middle and Eastern European countries (Czech Republic: 5.5/100 000 in 2010, Poland: 1.8/100 000 between 1990 and 2003, Romania: 0.97/100 000 between 2002 and 2003, Slovakia: 6.8/100 000 in 2013) \[[@pone.0233238.ref003], [@pone.0233238.ref013], [@pone.0233238.ref014], [@pone.0233238.ref015]\].

Most studies reported the peak incidence of UC in the early adulthood period (in the second to fourth decade); however, in some studies a second modest rise in incidence in latter decades of life was reported (between 50--70 years old) \[[@pone.0233238.ref005]\]. In some previous studies published from Hungary the peak onset age was between 21 and 40 years \[[@pone.0233238.ref008]\]. In contrast, two peaks in the onset of ulcerative colitis (30--39 years and over 50 years) was found in present study, which is similar to the findings of the Inflammatory Bowel South-Eastern Norway (IBSEN) Study Group \[[@pone.0233238.ref016]\]. In our study, the median age at diagnosis was higher than in previous studies, which is probably coming from the second peak of onset.

It is still questionable whether UC-patients are at higher risk of dying in contrast with the general population or not. Overall and cause-specific mortality was assessed by a meta-analysis of population-based inception cohort studies. They found that the overall mortality of UC patients was similar to the general population (the overall standardized mortality ratio of 1.1 (95% CI: 0.9--1.2, p = 0.42)); however, the cause-of-death distribution seemed to be different, with a higher risk of gastrointestinal diseases \[[@pone.0233238.ref010]\]. In our study only the overall mortality was assessed.

In contrast to the above-mentioned meta-analysis, our study revealed a significant difference (HR = 1.65) between the survival of patients with UC and that of the general population.

The most common malignancies of the Hungarian UC population were CRC, malignant neoplasm of skin, and malignant neoplasm of the prostate. These findings are in accordance with the results of a Danish population-based cohort study between 1962 and 1987. They found an increased risk for colorectal cancer and among men, for melanoma, but no increased risk for other cancers could be detected \[[@pone.0233238.ref017]\].

In our study 8.5% of the incident UC population were diagnosed with colorectal carcinoma between 2010--2016. The median age of the diagnosis of colorectal cancer was 65.8 years, which is higher than the average age previously published from Hungary, but similar to the general population \[[@pone.0233238.ref007]\]. Comparing the survival of younger and older populations, no significant difference was found between patients who were diagnosed with CRC at an age below or above 60. A study from 2006 found the incidence of CRC 2.5%, 7.6% and 10.8% after 20, 30 and 40 years of disease duration of UC, respectively \[[@pone.0233238.ref018]\]. A Swedish study of colonoscopic surveillance for UC found lower risk of CRC development, 2.0%, 3.0% and 9.4% at 20, 30 and 40 years. They found a threefold increased risk of CRC compared to the general population \[[@pone.0233238.ref019]\].

Our study has some strengths and limitations that should be mentioned. A nationwide claims and insurance database was used in the study which is based on the sole insurance fund in Hungary with close to full population coverage. A major limitation is the retrospective nature of the study, where the primary aim of the data collection was not the clinical evaluation of patients, but rather to serve financial and reimbursement purposes. Therefore, no data was available on clinical outcomes, such as laboratory values, disease severity indices, access to healthcare or patient reported outcomes. Dosing information on all pharmaceutical products was limited. Only all-cause deaths data could be analyzed, because cause of death data (cancer or disease-specific) were not available for all deaths and are highly inconsistent even when they were available. Therefore, cause of death was decided not to be analyzed in this study. Another major limitation of our study was the limited amount of information on the matched general population--only the date of death could be obtained in addition to the age (date of birth) and gender which the matching was based on.

Conclusion {#sec015}
==========

In conclusion, our nationwide, population-based study was the first to estimate the different malignancies and mortality data among Hungarian ulcerative colitis patients, and also updated previously available data of prevalence and incidence rates. Although the mortality trend of the Hungarian UC population is in concordance with the trend observable in the general population of Hungary, our results revealed a significantly worse survival of UC patients suffering from CRC than that of the general population. These findings emphasize the importance of colorectal cancer surveillance program in the management of UC.

Supporting information {#sec016}
======================

###### Minimal dataset derived from the database.

Sheet "Prevalence, Incidence"--Prevalent and incident patient numbers. Sheet "Demographics"--Patient counts in age groups, median, mean and standard deviation of age. Sheet "Deaths"--Raw death counts and median age at death. Sheet "Malignancies distribution"--Patient counts with malignancy diagnoses based on 3-digit ICD-10 code. Sheet "CRC epidemiology"--Patient counts with new CRC diagnoses, median age at CRC diagnosis and death, total death counts. Sheet "Survival1"--Survival curve data, OS, UC patients and controls. Sheet "Survival2"--Survival curve data, OS, CRC-UC patients, whole group and age stratified.

(XLSX)

###### 

Click here for additional data file.
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8\. It would be important to know whether the change in mortality from CRC in UC was unique to UC or whether this was similar as to the general population. This data should be collectable using your database and I would recommend including this as well.

Reviewer \#2: This is a population-based national study on UC and associated CRC mortality, among others. Administrative data is used. The authors find an increased risk of CRC-mortality in UC patients.

Abstract

1\. There is no clear description of the analytical methods used, including type of analysis, matching procedure.

2\. The aim in the methods section should be more appropriately located in the background section.

General

1\. The manuscript needs to be edited by a thorough English speaker.

Introduction

1\. The introduction is winding and overly long and could be shortened considerably. What does this study add, why was it done? What gap of knowledge exists and how could this study help\`?

Methods

2\. The aim should be placed in the introduction section, along with a clear hypothesis.

3\. The English is not up to par in the \"Data Collection\" section, making it difficult to follow. PLease revise.

4\. The described algorithm for identifying UC patients seems reasonable, though validity is not mentioned. Has this algorithm been tested against e.g. chart data, and with what results?

5\. Though I assume this to be the case, it should be mentioned that also the matched controls were also assessed for CRC using the described method for the UC patients (the cases).

6\. In the statistics section, there is no mention of missing data and how this was handled. Also, was the Cox model tested for assumptions?

Results

7\. The authors state that the decrease seen in UC incidence is a function of their diagnosis capture. This should be stated in the discussion, and how sure are the authors of this fact? MOreover, please analyse this statistically also (p value for difference/trend).

8\. It would be interesting to see the incidence of CRC in the matched population also.

9\. State p value for difference when comparing median survival in CRC UC versus non-CRC UC.

10\. Survival curves should have Life tables and log rank tests, perhaps also confidence intervals.

Discussion

11\. There is a paucity of other populationbased studies (apart from Hungarian ones) in the discussion. E.g. Rutegard 2016 Scand J Surg found 9% CRC incidence after 38 years of screening colonoscopy in a defined UC cohort and should be cited, along with the St Marks study (Rutter 2006 Gastroenterology). Is there any screening programmes for UC in Hungary?

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0233238.r002

Author response to Decision Letter 0

25 Feb 2020

Journal requirements:

1\. Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming.

We have updated the style of the manuscript, including numbering lines and reformatting figure labels.

2\. We noticed you have some minor occurrence(s) of overlapping text with publication(s).

We rephrased the above-mentioned parts of the manuscript. However, we made an effort to find the original article from

Saro Gismera C. et al. (1999) (<https://www.ncbi.nlm.nih.gov/pubmed/10231311>),

but since it was written in Spanish, and we don't speak Spanish, we were unable to find and rephrase the overlapping parts with our manuscript.

3\. In the ethics statement in the manuscript and in the online submission form, please provide additional information about the patient records/samples used in your retrospective study. Specifically, please ensure that you have discussed whether all data/samples were fully anonymized before you accessed them and/or whether the IRB or ethics committee waived the requirement for informed consent. If patients provided informed written consent to have data/samples from their medical records used in research, please include this information.

We have added the necessary information to both the manuscript and submission form.

The research team had access to anonymized data, the anonymization was performed by the data holder. The re-use of public data (which includes the data used in the study) is guaranteed by law in Hungary (based on Act 63/2012 on the re-use of public data).

The research group had access to the data indirectly, through NHIF according to internal data privacy regulations of NHIF and Regulation (EU) 2016/679 General Data Protection Regulation (GDPR). Due to this, and to the retrospective nature of the study there was no need for patient level consent to the analysis.

4\. Competing interests.

We would like to modify the competing interests statement to the following due to declarations that I had received after the initial submission was done:

I have read the journal's policy and the authors of this manuscript have the following competing interests:

PK, JGO, PT, ABo are employees / consultants of Janssen

PLL has been a speaker and/or advisory board member for AbbVie, Arena Pharmaceuticals, Celltrion, Falk Pharma GmbH, Ferring, Genetech, Janssen, Merck, Pharmacosmos, Pfizer, Roche, Shire and Takeda and has received unrestricted research grants from AbbVie, MSD and Pfizer.

TSz has served as advisory board member for AbbVie, EGIS, Pfizer and Takeda, received speaker's honoraria from Abbvie, Takeda and Ferring and served as part time medical advisor for Hungarian National Health Insurance Fund.

TM received speaker's honoraria from MSD, AbbVie, Egis, Goodwill Pharma, Takeda, Pfizer and Teva.

KF received speaker's honoraria from AbbVie, Janssen and Ferring.

ABá: received speaker's honoraria from Janssen and Ferring.

KSz, ÁM have no conflicts of interest to declare.

This does not alter our adherence to PLOS ONE policies on sharing data and materials.

5\. Data access

The dataset that was used is held by the National Health Insurance Fund (NHIF) of Hungary (<http://www.neak.gov.hu>, e-mail: <neak@neak.gov.hu>).

Access to the individual-level data is available after filing a formal data access request to <adatkeres@neak.gov.hu>. Requestors need to accept the terms and conditions of the data request and may need to pay the corresponding data access fee.

The terms of the contract for data access does not allow the reporting of any data of a single individual or results which comes from aggregating the data of less than 10 individuals. Therefore, a de-identified dataset could not be provided. Taking these requirements into consideration, the results can be published.

A supplementary dataset was created which contains the patient counts derived from the original data.

Reviewers' comments:

Reviewer \#1:

1\. As many may be unfamiliar with your healthcare database it would be helpful to have either a better description or a reference to a description of the database in the manuscript and some highlights as it pertains to this manuscript.

We revised the manuscript and added some information in the Data collection section about the database used.

2\. Endpoints need to be described better. Primary endpoints are endpoints that your study is powered to detect. Secondary endpoints are those which the study is not powered to detect. Just stating that you had 3 endpoints is not adequate.

We absolutely agree with the Reviewer that the phrasing „endpoint" is not the most appropriate word we used, as our study is purely descriptive in nature. We decided not to use this terminology at all and rephrased the above-mentioned part of the manuscript and moved these parts to the Methods section.

3\. I would advocate removing figure 2 altogether since you state that you cannot adequately determine the incidence. You do a nice job of explaining why, but that essentially renders most of your data in that table questionable at best. I think keeping he descriptive language is good enough for this.

Based on the Reviewer's suggestion, we revised the above-mentioned part of the Manuscript. Figure 2 was removed, and the paragraph has been shortened as well.

4\. On Figure 3, the legend at the top has the male label over the female plot and vv. I would recommend switching that order to make it easier to understand.

We made the suggested switch in the labelling.

5\. Figure 5 is too difficult to interpret. Please either include the names on the cancers on the Y axis or highlight and name some key cancers within the figure.

Using some abbreviations, it was possible to include the name of cancers on the Y axis. The caption of the figure was revised accordingly.

6\. Are deaths cancer-specific, disease-specific, or all cause? It seems like they are all cause but I think this needs to be highlighted better. This is also a big weakness of this manuscript because it is hard to know if these cancer patients had more severe disease, or accessed healthcare less and had other comorbidities. This should be discussed more in depth in the discussion.

We revised and completed the discussion and the limitations parts of the manuscript.

The primary aim of the data collection was not the clinical evaluation of patients, but rather to serve financial and reimbursement purposes. Therefore, no data were available on clinical outcomes, such as laboratory values, disease severity indices, access to healthcare or patient reported outcomes.

7\. Figure 8 is labeled poorly. It seems like it is CRC patients with UC, but from the labeling it appears to be all CRC patients in the country. This labeling should be improved upon.

We improved the labeling accordingly.

8\. It would be important to know whether the change in mortality from CRC in UC was unique to UC or whether this was similar as to the general population. This data should be collectable using your database and I would recommend including this as well.

Unfortunately, no information other than the date of birth, date of death and gender could be obtained for the general population in this study; therefore, no further analyses regarding these controls were possible.

We have clarified this circumstance in the Data collection and Discussion parts of the manuscript.

Reviewer \#2:

1\. Abstract -- There is no clear description of the analytical methods used, including type of analysis, matching procedure.

The study is descriptive in nature. We added this fact to the abstract. We also added some description of the matching procedure to the abstract.

2\. Abstract -- The aim in the methods section should be more appropriately located in the background section.

We made the change proposed, the aims were moved to the Introduction section.

The manuscript needs to be edited by a thorough English speaker.

We revised the language used and the manuscript was edited by a thorough English speaker. We hope it matches the journal standard.

1\. The introduction is winding and overly long and could be shortened considerably. What does this study add, why was it done? What gap of knowledge exists and how could this study help\`?

We have shortened the Introduction section by moving some of the content to the Discussion section. The background of the study and the aims of the study are clearly indicated in the revised text.

2\. The aim should be placed in the introduction section, along with a clear hypothesis.

We moved the aim section to the end of the introduction. Our study is a descriptive, retrospective, epidemiological study; therefore, no formal hypotheses were formulated.

3\. The English is not up to par in the \"Data Collection\" section, making it difficult to follow. Please revise.

We have revised the "Data Collection" section by adding more details to make it easier to understand. Some sentences were also deleted or rephrased.

4\. The described algorithm for identifying UC patients seems reasonable, though validity is not mentioned. Has this algorithm been tested against e.g. chart data, and with what results?

The algorithm is originated from a previous Hungarian study by Kurti et al. (doi: 10.1016/j.dld.2016.07.012). We lacked the necessary data to validate this algorithm ourselves.

5\. Though I assume this to be the case, it should be mentioned that also the matched controls were also assessed for CRC using the described method for the UC patients (the cases).

Unfortunately, no other data (comorbidities, etc.) except the date of birth, gender and the date of death could be obtained for the general population in this study; therefore, further analysis of the matched controls couldn't be performed.

We have clarified this circumstance in the Data collection and Discussion parts of the manuscript.

6\. In the statistics section, there is no mention of missing data and how this was handled. Also, was the Cox model tested for assumptions?

The Statistical analysis section was improved by inserting the following information:

Due to the claims nature of the data, missing data are undiscoverable in most cases. If a certain intervention or diagnosis was not recorded, there is no chance that it could be imputed in any way. Therefore, no handling of missing data was performed.

The proportional hazards assumption for the Cox model was tested using plots of Schoenfeld residuals.

7\. The authors state that the decrease seen in UC incidence is a function of their diagnosis capture. This should be stated in the discussion, and how sure are the authors of this fact? Moreover, please analyze this statistically also (p value for difference/trend).

Due to the unreliability of the results obtained, we have decided to reduce the information presented. Fig 2. was removed altogether and only a point prevalence for the year 2015 was presented. As this is explained in the results section, we did not see the need to repeat it in the discussion section.

8\. It would be interesting to see the incidence of CRC in the matched population also.

Unfortunately, no other data (comorbidities, etc.) except the date of birth, gender and the date of death could be obtained for the general population in this study; therefore, further analysis of the matched controls couldn't be performed.

We have clarified this circumstance in the Data collection and Discussion parts of the manuscript.

9\. State p value for difference when comparing median survival in CRC UC versus non-CRC UC.

Due to the obvious differences in the survival of CRC patients and all patients (5-year survival rates of 65% vs 86%), this formal analysis was not performed.

10\. Survival curves should have Life tables and log rank tests, perhaps also confidence intervals.

Life tables were added to the corresponding figures. The p-value for log-rank tests was also included to figures with comparisons. Shading was used to display the confidence intervals for the survival curves.

11\. There is a paucity of other population-based studies (apart from Hungarian ones) in the discussion. E.g. Rutegard 2016 Scand J Surg found 9% CRC incidence after 38 years of screening colonoscopy in a defined UC cohort and should be cited, along with the St Marks study (Rutter 2006 Gastroenterology). Is there any screening programmes for UC in Hungary?

We revised the discussion section and added the mentioned population-based studies.

The CRC-screening program has been started in 2019, before that, some pilot studies were conducted. No special UC-CRC screening program is available yet in Hungary, but we follow the ECCO-guidelines on outpatient follow-up visits.
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16 Mar 2020

PONE-D-19-32655R1

Epidemiology, mortality and prevalence of colorectal cancer in ulcerative colitis patients between 2010-2016 in Hungary -- a population-based study

PLOS ONE

Dear Mr. Kunovszki,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

We would appreciate receiving your revised manuscript by Apr 30 2020 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Valérie Pittet, PhD

Academic Editor

PLOS ONE

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

Reviewer \#2: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: No

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: Thank you for addressing our concerns. The introduction is still quite difficult to read and I would recommend having a native English speaker rewrite it prior to acceptance.

Reviewer \#2: The authors have responded adequately to most questions and I can only recommend publication. Please note that Figure 6 seems to be inverted, i.e. have cases and controls been mixed up? Seems strange that the colitis should be both bigger and more prone to survive, given the increased HR for this group stated in the manuscript.

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0233238.r004

Author response to Decision Letter 1

29 Apr 2020

Reviewer \#1:

The Reviewer indicated that the authors did not make all data underlying the findings in the manuscript fully available.

Please note that due to legal and ethical restrictions, the patient level data could not be made available. Please also note that a supplementary dataset containing aggregated data based on the original patient-level data was created and made available with the submission.

Please refer to the data availability statement (quoted below) for further information.

The dataset that was used is held by the National Health Insurance Fund (NHIF) of Hungary (<http://www.neak.gov.hu>, e-mail: <neak@neak.gov.hu>).

Access to the individual-level data is available after filing a formal data access request to <adatkeres@neak.gov.hu>. Requestors need to accept the terms and conditions of the data request and may need to pay the corresponding data access fee.

The terms of the contract for data access does not allow the reporting of any data of a single individual or results which comes from aggregating the data of less than 10 individuals. Therefore, a de-identified dataset could not be provided. Taking these requirements into consideration, the results can be published.

A supplementary dataset was created which contains the patient counts derived from the original data.

The introduction is still quite difficult to read and I would recommend having a native English speaker rewrite it prior to acceptance.

The whole manuscript was checked for stylistic and grammatical errors and some minor changes were made throughout.

Reviewer \#2:

Please note that Figure 6 seems to be inverted, i.e. have cases and controls been mixed up? Seems strange that the colitis should be both bigger and more prone to survive, given the increased HR for this group stated in the manuscript.

Thank you for catching our mistake. Some kind of technical error occurred while creating the graph. We have addressed the issue and the graph is resubmitted.

10.1371/journal.pone.0233238.r005
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PONE-D-19-32655R2

Dear Dr. Kunovszki,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

With kind regards,

Valérie Pittet, PhD

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers\' comments:
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5 May 2020

PONE-D-19-32655R2

Epidemiology, mortality and prevalence of colorectal cancer in ulcerative colitis patients between 2010-2016 in Hungary -- a population-based study

Dear Dr. Kunovszki:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

For any other questions or concerns, please email <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff

on behalf of

PD Dr. Valérie Pittet

Academic Editor

PLOS ONE

[^1]: **Competing Interests:**I have read the journal's policy and the authors of this manuscript have the following competing interests: PK, JGO, PT, ABo are employees / consultants of Janssen. PLL has been a speaker and/or advisory board member for AbbVie, Arena Pharmaceuticals, Celltrion, Falk Pharma GmbH, Ferring, Genetech, Janssen, Merck, Pharmacosmos, Pfizer, Roche, Shire and Takeda and has received unrestricted research grants from AbbVie, MSD and Pfizer. TSz has served as advisory board member for AbbVie, EGIS, Pfizer and Takeda, received speaker's honoraria from Abbvie, Takeda and Ferring and served as part time medical advisor for Hungarian National Health Insurance Fund. TM received speaker's honoraria from MSD, AbbVie, Egis, Goodwill Pharma, Takeda, Pfizer and Teva. KF received speaker's honoraria from AbbVie, Janssen and Ferring. ABá: received speaker's honoraria from Janssen and Ferring. KSz, ÁM have no conflicts of interest to declare. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
